Multiple Myeloma Specialty Channel

Multiple Myeloma

Specialty Channel

News

Nivolumab, Pomalidomide, and Elotuzumab Combination for Patients With R/R Multiple Myeloma

10/10/2024

Nivolumab plus pomalidomide and dexamethasone plus or minus elotuzumab did not demonstrate a clinical benefit compared with pomalidomide and dexamethasone treatment for patients with relapsed/refractory multiple myeloma, according to phase 3...

Nivolumab plus pomalidomide and...

10/10/2024

Oncology

News

Belantamab Mafodotin Plus Pomalidomide-Dexamethasone Demonstrates Efficacy Among Patients With Triple Class Exposed/Refractory Multiple Myeloma

09/26/2024

Amber Denham ;

Patients with triple class exposed/refractory multiple myeloma treated with belantamab mafodotin plus pomalidomide-dexamethasone achieved high clinical response rates with durable remissions, determined a post-hoc analysis of the ALGONQUIN...

Patients with triple class...

09/26/2024

Oncology

FDA Approval

FDA Grants Approval to Isatuximab With Bortezomib, Lenalidomide, and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma Not Eligible for ASCT

09/20/2024

Amber Denham ;

The US Food and Drug Administration granted approval to isatuximab with bortezomib, lenalidomide, and dexamethasone for the frontline treatment of patients with multiple myeloma who are not eligible for autologous stem cell transplant.

The US Food and Drug...

09/20/2024

Oncology

Quiz

Weekly Combination Therapy for Patients With R/R Multiple Myeloma

07/11/2024

Oncology

News

Weekly Carfilzomib, Pomalidomide, and Dexamethasone Demonstrates Efficacy for Patients With R/R Multiple Myeloma

07/09/2024

Amber Denham ;

Phase 2 results from the SELECT study demonstrated that weekly carfilzomib, pomalidomide, and dexamethasone treatment showed efficacy and tolerability among patients with relapsed/refractory multiple myeloma.

Phase 2 results from the SELECT...

07/09/2024

Oncology

News

Teclistamab Provides Deep, Durable Response Among Heavily Pretreated Patients With R/R Multiple Myeloma

05/20/2024

Amber Denham

According to results from a multi-institutional real-world study, teclistamab yielded rapid achievement of deep hematologic response among heavily pre-treated patients with relapsed/refractory multiple myeloma.

According to results from a...

05/20/2024

Oncology

News

Elranatamab vs Teclistamab Treatment Among Patients With Triple-Class Exposed/Refractory Multiple Myeloma

04/19/2024

Jordan Kadish

According to findings from an unanchored matching-adjusted indirect comparison, elranatamab exhibited significantly better response and survival outcomes among patients with triple-class exposed/refractory multiple myeloma, compared with...

According to findings from an...

04/19/2024

Oncology

News

Idecabtagene Vicleucel Improves Health-Related Quality of Life Compared With Standard Therapeutic Regimens for Patients With R/R MM

04/09/2024

Amber Denham

According to phase 3 data from the KarMMa-3 trial, the CAR T-cell therapy idecabtagene vicleucel demonstrates improved health-related quality of life compared with standard regimens among patients with relapsed/refractory multiple myeloma...

According to phase 3 data from...

04/09/2024

Oncology

News

Real-World Triple-Class Exposed Patients With R/R MM Receiving a Subsequent Line of Treatment Exhibit Poor Outcomes

04/02/2024

Jordan Kadish

Real-world triple-class exposed patients with relapsed/refractory multiple myeloma who received a subsequent line of treatment exhibited poor outcomes, according to a retrospective observational cohort study.

Real-world triple-class exposed...

04/02/2024

Oncology

News

Bortezomib, Lenalidomide, and Dexamethasone Maintenance Therapy Does Not Show Improved Outcomes for Patients With High-Risk Multiple Myeloma

04/01/2024

Amber Denham

According to a long-term updated analysis, 3 years of bortezomib, lenalidomide, and dexamethasone maintenance did not improve outcomes for patients with high-risk multiple myeloma defined by gene expression profiling.

According to a long-term updated...

04/01/2024

Oncology

News

Novel Predictive Model May Provide Strategic Insights for CAR T-Cell Therapy for Patients With R/R MM

03/18/2024

Amber Denham

The novel myeloma CAR T Relapse prognostic model may be useful in strategizing optimal timing of CAR T-cell therapy in certain subgroups of patients with R/R MM, according to an international, retrospective study.

The novel myeloma CAR T Relapse...

03/18/2024

Oncology

News

Nivolumab, Pomalidomide, and Elotuzumab Combination for Patients With R/R Multiple Myeloma

10/10/2024

Amber Denham ;

Nivolumab plus pomalidomide and...

10/10/2024

Oncology

News

Belantamab Mafodotin Plus Pomalidomide-Dexamethasone Demonstrates Efficacy Among Patients With Triple Class Exposed/Refractory Multiple Myeloma

09/26/2024

Amber Denham ;

Patients with triple class...

09/26/2024

Oncology

FDA Approval

FDA Grants Approval to Isatuximab With Bortezomib, Lenalidomide, and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma Not Eligible for ASCT

09/20/2024

Amber Denham ;

The US Food and Drug...

09/20/2024

Oncology

News

Weekly Carfilzomib, Pomalidomide, and Dexamethasone Demonstrates Efficacy for Patients With R/R Multiple Myeloma

07/09/2024

Amber Denham ;

Phase 2 results from the SELECT...

07/09/2024

Oncology

News

Teclistamab Provides Deep, Durable Response Among Heavily Pretreated Patients With R/R Multiple Myeloma

05/20/2024

Amber Denham

According to results from a...

05/20/2024

Oncology

News

Elranatamab vs Teclistamab Treatment Among Patients With Triple-Class Exposed/Refractory Multiple Myeloma

04/19/2024

Jordan Kadish

According to findings from an...

04/19/2024

Oncology

News

Idecabtagene Vicleucel Improves Health-Related Quality of Life Compared With Standard Therapeutic Regimens for Patients With R/R MM

04/09/2024

Amber Denham

According to phase 3 data from...

04/09/2024

Oncology

News

Real-World Triple-Class Exposed Patients With R/R MM Receiving a Subsequent Line of Treatment Exhibit Poor Outcomes

04/02/2024

Jordan Kadish

Real-world triple-class exposed...

04/02/2024

Oncology

News

Bortezomib, Lenalidomide, and Dexamethasone Maintenance Therapy Does Not Show Improved Outcomes for Patients With High-Risk Multiple Myeloma

04/01/2024

Amber Denham

According to a long-term updated...

04/01/2024

Oncology

News

Novel Predictive Model May Provide Strategic Insights for CAR T-Cell Therapy for Patients With R/R MM

03/18/2024

Amber Denham

The novel myeloma CAR T Relapse...

03/18/2024

Oncology

Interactive Features

Quiz

Weekly Combination Therapy for Patients With R/R Multiple Myeloma

07/11/2024

Oncology

Quiz

Treating R/R Multiple Myeloma With Fractionated BCMA-Directed CAR T-Cell Therapy ARI0002h

01/30/2024

According to an interim analysis from the CARTBCMA-HCB-01 pilot study, ARI0002h, a BCMA-targeted CAR T-cell therapy developed within the academic setting, demonstrated encouraging responses when administered in a fractionated manner with a...

According to an interim analysis...

01/30/2024

Oncology

Quiz

Mezigdomide Plus Dexamethasone Oral Combination for Patients With Heavily Pretreated R/R MM

01/19/2024

True or False: The oral combination of mezigdomide plus dexamethasone demonstrated promising efficacy among patients with heavily pretreated, relapsed/refractory (R/R) multiple myeloma (MM), according to findings from a phase 1/2 study.

True or False: The oral...

01/19/2024

Oncology

Quiz

Quiz: Ciltacabtagene Autoleucel CAR T-Cell Therapy for Patients With R/R Multiple Myeloma With Prior BCMA-Targeting Therapy

04/18/2023

In a study assessing the efficacy and safety of ciltacabtagene autoleucel CAR-T-cell therapy among patients with R/R multiple myeloma who had been previously exposed to noncellular anti-B-cell maturation antigen therapies, what was the...

In a study assessing the...

04/18/2023

Oncology

Quiz

Quiz: Triplet Therapy With Lenalidomide, Bortezomib, and Dexamethasone Alone or With Autologous SCT for MM

09/13/2022

True or False: Among adults with multiple myeloma, triplet therapy with lenalidomide, bortezomib, and dexamethasone (RVD) plus autologous stem-cell transplantation was associated with longer progression-free survival than RVD alone, according...

True or False: Among adults with...

09/13/2022

Oncology

Quiz

Quiz: Responses to MRD-Adapted Study Design Employing Quadruplet Therapy Without Transplant in Patients With MM

09/02/2022

True or false: In a phase 2 study, an MRD-adapted study design employing a quadruplet therapy regimen of elotuzumab with weekly carfilzomib, lenalidomide, and dexamethasone without transplant was associated with deep, durable responses in...

True or false: In a phase 2...

09/02/2022

Oncology

Quiz

Quiz: Treatment With Teclistamab for Patients With Triple-Class Exposed Relapsed/Refractory MM

08/24/2022

Quiz: Among patients with triple-class exposed relapsed/refractory MM on a phase 1-2 study, treatment with teclistamab led to an overall response rate of which of the following?

Quiz: Among patients with...

08/24/2022

Oncology

Test Your Knowledge

Quiz: Is TNB-383B Well Tolerated in R/R MM?

02/01/2022

True or false: TNB-383B, a BCMA x CD3 T-cell engaging bispecific antibody, is not well tolerated in patients with R/R MM.

True or false: TNB-383B, a BCMA...

02/01/2022

Oncology

Test Your Knowledge

Quiz: Do Gamma Secretase Inhibitors Increase BCMA Expression?

02/01/2022

True or false: Gamma secretase inhibitors increase BCMA expression on MM cells.

True or false: Gamma secretase...

02/01/2022

Oncology

Test Your Knowledge

Quiz: Does Teclistamab Target Both BCMA and CD3 Receptors for MM?

01/27/2022

True or false: Teclistamab targets both BCMA and CD3 receptors to induce T-cell mediated cytotoxicity of BCMA-expressive myeloma cells.

True or false: Teclistamab...

01/27/2022

Oncology

Recent News

News

Nivolumab, Pomalidomide, and Elotuzumab Combination for Patients With R/R Multiple Myeloma

10/10/2024

Amber Denham ;

Nivolumab plus pomalidomide and...

10/10/2024

Oncology

News

Belantamab Mafodotin Plus Pomalidomide-Dexamethasone Demonstrates Efficacy Among Patients With Triple Class Exposed/Refractory Multiple Myeloma

09/26/2024

Amber Denham ;

Patients with triple class...

09/26/2024

Oncology

FDA Approval

FDA Grants Approval to Isatuximab With Bortezomib, Lenalidomide, and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma Not Eligible for ASCT

09/20/2024

Amber Denham ;

The US Food and Drug...

09/20/2024

Oncology

News

Weekly Carfilzomib, Pomalidomide, and Dexamethasone Demonstrates Efficacy for Patients With R/R Multiple Myeloma

07/09/2024

Amber Denham ;

Phase 2 results from the SELECT...

07/09/2024

Oncology

News

Teclistamab Provides Deep, Durable Response Among Heavily Pretreated Patients With R/R Multiple Myeloma

05/20/2024

Amber Denham

According to results from a...

05/20/2024

Oncology

News

Elranatamab vs Teclistamab Treatment Among Patients With Triple-Class Exposed/Refractory Multiple Myeloma

04/19/2024

Jordan Kadish

According to findings from an...

04/19/2024

Oncology

News

Idecabtagene Vicleucel Improves Health-Related Quality of Life Compared With Standard Therapeutic Regimens for Patients With R/R MM

04/09/2024

Amber Denham

According to phase 3 data from...

04/09/2024

Oncology

News

Real-World Triple-Class Exposed Patients With R/R MM Receiving a Subsequent Line of Treatment Exhibit Poor Outcomes

04/02/2024

Jordan Kadish

Real-world triple-class exposed...

04/02/2024

Oncology

News

Bortezomib, Lenalidomide, and Dexamethasone Maintenance Therapy Does Not Show Improved Outcomes for Patients With High-Risk Multiple Myeloma

04/01/2024

Amber Denham

According to a long-term updated...

04/01/2024

Oncology

News

Novel Predictive Model May Provide Strategic Insights for CAR T-Cell Therapy for Patients With R/R MM

03/18/2024

Amber Denham

The novel myeloma CAR T Relapse...

03/18/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology